<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418535</url>
  </required_header>
  <id_info>
    <org_study_id>2004-10-08</org_study_id>
    <nct_id>NCT00418535</nct_id>
  </id_info>
  <brief_title>Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma</brief_title>
  <official_title>A Phase II Study of Concurrent Chemoradiation Followed by VIPD (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) in Stage I, II Nasal NK/T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      Nasal NK/T-cell lymphoma is a peculiar clinico-pathologic subtype of non-Hodgkin's lymphoma
      (NHL). Although most patients present with stage I/II, only 30-60% of the patients remain
      disease-free. The efficacy of the conventional anthracycline-based chemotherapy
      (cyclophosphamide, doxorubicin, vincristine, prednisone [CHOPP]) has been unsatisfactory.

      The optimal treatment of localized NK/T-cell lymphoma has not been defined yet. The optimal
      dose, sequence, and multi-modality treatment with involved field radiotherapy still need to
      be refined. This trial is to evaluate the efficacy of concurrent chemoradiotherapy with
      cisplatin followed by VIPD (etoposide, ifosfamide, cisplatin, dexamethasone) in localized
      NK/T-cell lymphoma patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphoma, T-Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent Radiotherapy (RT)/cisplatin, VIPD</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed NK/T-cell lymphoma

          -  Localized (Ann Arbor stage I/II) disease

          -  At least one measurable lesion

          -  Age &gt; 18

          -  ECOG performance status 0 - 2

          -  Expected life span of at least 12 weeks

          -  Normal marrow function (hemoglobin ≥ 9.0 g/dL; absolute neutrophil count ≥ 1,500/mm3;
             platelet count ≥ 100,000/mm3)

          -  Normal liver function (total bilirubin &lt; 2x upper limit of normal [ULN], transaminase
             &lt; 3x ULN)

          -  Normal renal function (serum creatinine ≤ 1.5 mg/dL, creatinine clearance ≥ 50 mL/min)

          -  Written informed consent

        Exclusion Criteria:

          -  Other malignancies except for treated non-melanoma skin cancers and cervical cancer in
             situ

          -  Serious medical illnesses (congestive heart failure, angina, respiratory failure, and
             renal failure)

          -  Acute or active infection requiring intravenous (IV) antibiotics

          -  Pregnant, lactating women

          -  Previous history of chemotherapy or radiotherapy

          -  Concomitant medication that may influence the study drugs

          -  Allergic reaction to study drugs

          -  Grade 2 or greater peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Seog Kim, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2007</study_first_posted>
  <last_update_submitted>October 20, 2009</last_update_submitted>
  <last_update_submitted_qc>October 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>CISL (Consortium to Improve Lymphoma Survival)</name_title>
    <organization>CISL (Consortium to Improve Lymphoma Survival)</organization>
  </responsible_party>
  <keyword>Lymphoma, NK/T-Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

